I perceive... a dearth of voices speaking out against the modern anti-vaccination movement. Their false claims and public statements more often than … - Peter J. Hotez

The reason why we have this situation now with Omicron... is we allowed large unvaccinated populations in low- and middle-income countries to remain unvaccinated. Delta arose out of an unvaccinated population in India in early 2021, and Omicron out of a large unvaccinated population on the African continent later in the same year. So, these two variants of concern represent failures, failures by global leaders to work with sub-Saharan Africa, Southeast Asia and Latin America to vaccinate the Southern Hemisphere, vaccinate the Global South.... myself...Dr. Bottazzi... and our team of 20 scientists... make vaccines for diseases that the pharma companies won’t make... the only thing we know how to do is make low-cost, straightforward vaccines for use in resource-poor settings... it was very difficult to get funding. We got no support from Operation Warp Speed, no support really from the G7 countries... now we’ve licensed our prototype vaccine, and help in the co-development, to India, Indonesia, Bangladesh and now Botswana.... it’s really exciting to show that, you know, you don’t need to be a multinational pharmaceutical company and just make brand-new technologies that will only be suitable for the Northern Hemisphere. We can really make a vaccine for the world.

In 2011, together with a team of 15 scientists, I relocated to Houston, Texas, to launch a new school devoted to poverty-related diseases. The National School of Tropical Medicine at is a joint venture among three biomedical institutions—Baylor, , and the —with a mission devoted to research on and training in the treatment of neglected tropical diseases, or NTDs...

When the Chinese started putting up the data on Bioarchive in January-February, we saw a very close homology between the two, and realized that we may be sitting on a very attractive Coronavirus vaccine. Now, we're working... again with NIH, and we're working with BARDA and others to get the funding, but now we'll have that lag. ...[T]hese clinical trials are not going to go that quickly because of that immune enhancement. It's going to take time. ...[U]nfortunsately, some of my colleagues in the biotech industry are making these inflated claims. ...[Y]ou've seen this... in the newspapers, "We're going to have this vaccine in weeks..." What they're really seeing is that they can move a vaccine into clinical trials, but this will not go quickly because as we start vaccinating human volunteers, especially in areas where we have community transmission, we're going to have to proceed very slowly, very cautiously. The FDA is on top of that. They have a great team in place at the . They're aware of the problem, but it's not going to go quickly. We are going to have to follow this very slowly, cautiously, to make certain that we're not seeing that immune enhancement. So now we're hearing projections, a year, 18 months, who knows...